JP2016536568A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536568A5
JP2016536568A5 JP2016515521A JP2016515521A JP2016536568A5 JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5 JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5
Authority
JP
Japan
Prior art keywords
autoantibodies
ovarian cancer
autoantibody
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515521A
Other languages
English (en)
Japanese (ja)
Other versions
JP6588893B2 (ja
JP2016536568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000925 external-priority patent/WO2015039175A1/en
Publication of JP2016536568A publication Critical patent/JP2016536568A/ja
Publication of JP2016536568A5 publication Critical patent/JP2016536568A5/ja
Application granted granted Critical
Publication of JP6588893B2 publication Critical patent/JP6588893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515521A 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー Active JP6588893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903595A AU2013903595A0 (en) 2013-09-18 Autoantibody biomarkers of ovarian cancer
AU2013903595 2013-09-18
PCT/AU2014/000925 WO2015039175A1 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Publications (3)

Publication Number Publication Date
JP2016536568A JP2016536568A (ja) 2016-11-24
JP2016536568A5 true JP2016536568A5 (enExample) 2017-10-26
JP6588893B2 JP6588893B2 (ja) 2019-10-09

Family

ID=52687999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515521A Active JP6588893B2 (ja) 2013-09-18 2014-09-18 卵巣がんの自己抗体バイオマーカー

Country Status (7)

Country Link
US (3) US20160291025A1 (enExample)
EP (1) EP3047277B1 (enExample)
JP (1) JP6588893B2 (enExample)
CN (1) CN105745543B (enExample)
AU (1) AU2014324080B2 (enExample)
CA (1) CA2924600A1 (enExample)
WO (1) WO2015039175A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056888A (zh) * 2017-03-01 2017-08-18 中山大学肿瘤防治中心 Atp1a1靶向多肽及应用
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
JP2022522803A (ja) * 2019-03-01 2022-04-20 アドバンスド マーカー ディスカバリー エセ. エレ. 結腸直腸癌及び/又はその前癌段階の診断用タンパク質シグネチャー
WO2021077026A1 (en) * 2019-10-16 2021-04-22 Icahn School Of Medicine At Mount Sinai Systems and methods for detecting a disease condition
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395935T1 (de) * 1999-03-15 2008-06-15 Univ Maryland An der oberfläche von karzinomzellen lokalisiertes colligin/hsp47
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
AU2001253104A1 (en) * 2000-04-03 2001-10-15 Gesellschaft Fur Biotechnologische Forschung Gmbh Methods for altering t cell and macrophage activation
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
KR20110019357A (ko) * 2002-08-06 2011-02-25 더 존스 홉킨스 유니버시티 난소암의 검출을 위한 생물 마커의 용도
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
AU2007211085A1 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
EP2062053B1 (en) * 2006-09-13 2012-12-05 Oncimmune LTD Improved immunoassay methods
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
CA2691980C (en) * 2007-06-29 2022-05-10 Correlogic Systems, Inc. Predictive markers for ovarian cancer
BRPI0820564A2 (pt) * 2007-11-13 2017-05-23 Phoenix Biotechnology Inc método para determinar a probabilidade de uma resposta terapêutica na quimioterapia do câncer com glicosídeo cardíaco
CN102171569A (zh) * 2008-05-09 2011-08-31 杜克大学 检测和治疗癌症的自身抗体
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
WO2010102195A2 (en) * 2009-03-06 2010-09-10 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
US20120277326A1 (en) 2009-11-20 2012-11-01 Taylor Douglas D Biomarkers of cancer
JP2011257147A (ja) * 2010-06-04 2011-12-22 Nitto Boseki Co Ltd データ収集方法、キット及び腫瘍マーカー
AU2013212000B2 (en) * 2012-01-26 2017-03-30 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
US20140179808A1 (en) * 2012-10-23 2014-06-26 Bio-Rad Laboratories, Inc. Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens
EP2951592A4 (en) 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer

Similar Documents

Publication Publication Date Title
JP2016536568A5 (enExample)
Kim et al. Hepatocellular carcinoma: old friends and new tricks
Hu et al. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage
Wan et al. New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell marker and circulating tumor microemboli in hepatocellular carcinoma
Vallböhmer et al. Molecular determinants of cetuximab efficacy
Kim et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival
Sadeghi et al. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma
Wang et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer
Zhu et al. B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer
Schrödter et al. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma
Xie et al. LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma
Rubie et al. Enhanced expression and clinical significance of CC‐chemokine MIP‐3α in hepatocellular carcinoma
Kleinberg et al. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Duan et al. Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine
EP3230745B1 (en) Plasma autoantibody biomarkers for basal like breast cancer
Frick et al. CCR 6/CCL 20 Chemokine Expression Profile in Distinct Colorectal Malignancies
Wimberger et al. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer
Usó et al. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
CN106233143B (zh) 癌症治疗
Li et al. CCL 20‐CCR 6 Cytokine Network Facilitate Treg Activity in Advanced Grades and Metastatic Variants of Hepatocellular Carcinoma
Li et al. Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study
Duan et al. Microfluidic immunoassay system for rapid detection and semi-quantitative determination of a potential serum biomarker mesothelin
WO2014198995A1 (es) Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas
Hugen et al. Circulating tumor cells in genitourinary malignancies: an evolving path to precision medicine
Carrasco-Torres et al. The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker